

**BILL SUMMARY**  
1<sup>st</sup> Session of the 60<sup>th</sup> Legislature

<b>Bill No.:</b>	<b>HB2801</b>
<b>Version:</b>	<b>INT</b>
<b>Request Number:</b>	<b>11293</b>
<b>Author:</b>	<b>Rep. Marti</b>
<b>Date:</b>	<b>2/4/2025</b>
<b>Impact:</b>	<b>\$5,053,253 - \$7,611,804</b>

**Research Analysis**

HB 2801, as introduced, provides that the Oklahoma Health Care Authority must approve a prior authorization request for any FDA approved atypical antipsychotic not on the preferred drug list for the treatment and prevention of mood disorders with psychotic symptoms. Medications included under this must be available at the same parity to other branded medications in the same class. Approval will be based on if there was a trial and failure of an approved atypical antipsychotic in the last year or if the patient is stable on an atypical antipsychotic not on the preferred drug list.

Prepared By: Suzie Nahach

**Fiscal Analysis**

HB 2801 directs the Oklahoma Health Care Authority (OHCA) to approve prior authorization requests for any FDA atypical antipsychotic not on the preferred drug list for the treatment of mood disorders. Medications are to be available at parity to branded medications in the same class.

OHCA anticipates an impact ranging from \$5,053,253 to \$7,611,804 due to the provisions of the measure.

Prepared By: Alexandra Ladner, House Fiscal Staff

**Other Considerations**

None.